TEM

Company Overview — What Does Tempus AI, Inc. Do?

We endeavor to unlock the true power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence, or AI, in healthcare. Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal. We make tests intelligent by connecting laboratory results to a patient’s own clinical data, thereby personalizing the results. Our novel insight was realizing that all laboratory test results, genomic or otherwise, could be contextualized for a specific patient based upon that patient’s unique characteristics, and technology could therefore guide therapy selection and treatment decisions to allow each patient to progress on their own unique path. The drugs recommended, the clinical trials explored, the care pathways evaluated, the adverse events considered—all have the potential to be refined and enhanced when test results are connected to a patient’s personal profile, enabling the right patient to be routed to the right therapy at the right time. To accomplish this, we built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Our proprietary technology has allowed us to amass what we consider to be one of the largest libraries of clinical and molecular oncology data in the world. Our goal is to embed AI, including generative AI, throughout every aspect of diagnostics to enable physicians and researchers to make personalized, data-driven decisions that improve patient care. The ability to deploy AI in precision medicine at scale has only recently become possible. Advances in cloud computing, imaging technologies, large language models, and low-cost molecular profiling, along with the digitization of vast amounts of healthcare data, have created a landscape that we believe is finally ripe for AI. However, despite an increase in the availability of healthcare data, physicians and researchers are largely unable today to leverage this data to improve patient care. The vast majority of healthcare data remains disconnected and lacks harmonization and structure. Traditional diagnostic tests are typically based only on a single data modality, such as a blood- based biomarker or a genomic mutation, and do not connect and integrate other forms of relevant clinical data, such as outcomes, or adverse events, or pathology results, which are essential for many clinical decisions. In order to bring AI to healthcare at scale, we began by rebuilding the foundation of how data flows in and out of healthcare institutions. We established data pipes, going to and from providers, to allow for the free exchange of data between physicians, who interpret data, and diagnostic and life science companies, who provide data. Without this capability, we believe that data could continue to accumulate without impacting patient care. Tempus has built this integrated Platform, and we are now deploying it at scale in the United States in oncology, and other areas, including neuropsychiatry, radiology, and cardiology, with aspirations to eventually be in all major disease areas globally. Our Platform connects multiple stakeholders within the larger healthcare ecosystem, often in near real time, to assemble and integrate the data we collect, thereby providing an opportunity for physicians to make data-driven decisions in the clinic and for researchers to discover and develop therapeutics. Tempus is a technology company focused on healthcare that straddles two converging worlds. We strive to combine deep healthcare expertise, providing next-generation diagnostics across multiple disease areas, with leading technology capabilities, harnessing the power of data and analytics to help personalize medicine. Unlike traditional diagnostic labs, we can incorporate unique patient information, such as clinical, molecular, and imaging data, with the goal of making our tests more intelligent and our results more insightful. Unlike other technology companies, we are deeply rooted in clinical care delivery as one of the largest sequencers of patients in the United States. Straddling both worlds is advantageous as we believe Intelligent Diagnostics represent the future of precision medicine, informing more personalized and data-driven therapy selection and development. Our Platform includes proprietary software and dedicated data pipelines that create a network of healthcare institutions through approximately 450 unique data connections, many of which supply us with complex multimodal data in near real time, across more than 2,000 healthcare institutions that order our products and services. Healthcare institutions supply us with this data in our capacity as a covered entity (for example, when we provide Next Generation Sequencing, or NGS, services on behalf of a patient), or as a business associate (for example, when we provide clinical trial matching services or data de-identification and structuring services). In addition to the data we receive in these capacities, we currently have a limited number of paid license agreements through which we acquire de-identified data directly from healthcare associations or institutions, and in certain circumstances we cover the actual direct costs associated with the technical integrations needed to create a data connection. We then integrate this data into a unified multimodal database through which we offer numerous analytical and decision support capabilities to our customers. We establish dedicated and integrated data connections with healthcare institutions to enhance the information we provide in our clinical reports, to increase the effectiveness of our clinical trial matching services, and to enable our AI Applications product line, which we believe has the ability to transform healthcare. We have launched a suite of different products derived from our Platform, which have gained significant traction over the past five years. To date, our offerings have been used by approximately 95% of the largest public pharmaceutical companies based on 2023 revenue, and our clinical NGS volume in oncology rose from approximately 31,000 samples in 2018 to approximately 288,000 samples in 2023. Through March 31, 2024, our offerings have been used by more than 7,000 physicians across hundreds of provider networks, including more than 65% of all academic medical centers in the United States. Our database of multimodal, de-identified records has grown to be more than 50 times the size of The Cancer Genome Atlas, the largest public genomic dataset that we know of in oncology. We also now have more than 200 petabytes of data in our cloud environment. Between our sequencing and data collection efforts, we are connected in some way to more than 50% of all oncologists practicing in the United States. Our access to broad and diverse data serves as the basis for our ability to train generative AI models, and we believe our relationships with healthcare institutions provide us with proprietary data to deliver on the promise of AI in healthcare. We originally set out to build a sustainable business model in oncology as our first proof of concept. To date, we have focused primarily on establishing and growing our oncology business, which represents the majority of both the data we have amassed and our revenue. Even though our cancer business was at an early stage, we next expanded into neuropsychiatry, as we believed our model was extensible across disease areas. Having gained early traction in depression, we then expanded into the radiology and cardiology categories. Each time we enter a new disease area we look to expand upon the model we deployed in oncology by developing Intelligent Diagnostics connected to clinical data, and by leveraging large amounts of de-identified data to advance patient care and accelerate drug discovery and development. Once we obtain sufficient data, which we can leverage as a proprietary training data set for generative AI applications, we expect to deploy our AI and machine learning capabilities to build algorithmic diagnostics at scale across diseases. We were founded by Eric Lefkofsky, originally formed under the name Bioin LLC in Delaware in August 2015 and we converted to a Delaware corporation in September 2015 under the name Bioin Inc. We changed our name to Tempus Health, Inc. later in 2015, to Tempus Labs, Inc. in 2016 and in 2023, we changed our name to Tempus AI, Inc. Our principal executive offices are located at 600 West Chicago Avenue, Suite 510 Chicago, Illinois. Tempus AI, Inc. (TEM) is classified as a mid-cap stock in the Technology sector, specifically within the Computer Software industry. The company is led by CEO Eric Lefkofsky, headquartered in CHICAGO, Illinois. With a market capitalization of $8.4B, TEM is one of the notable companies in the Technology sector.

Tempus AI, Inc. (TEM) Stock Rating — Avoid (April 2026)

As of April 2026, Tempus AI, Inc. receives a Avoid rating with a composite score of 26.8/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.TEM ranks #4,048 out of 4,446 stocks in our coverage universe. Within the Technology sector, Tempus AI, Inc. ranks #507 of 584 stocks, placing it in the lower half of its Technology peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TEM Stock Price and 52-Week Range

Tempus AI, Inc. (TEM) currently trades at $45.37. The stock gained $1.21 (2.7%) in the most recent trading session. The 52-week high for TEM is $104.32, which means the stock is currently trading -56.5% from its annual peak. The 52-week low is $36.22, putting the stock 25.3% above its annual trough. Recent trading volume was 1.2M shares, reflecting moderate market activity.

Is TEM Overvalued or Undervalued? — Valuation Analysis

Tempus AI, Inc. (TEM) carries a value factor score of 30/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 17.03x, versus the sector average of 3.16x. The price-to-sales ratio is 7.71x, compared to 1.06x for the average Technology stock.

At current multiples, Tempus AI, Inc. trades at a premium to most Technology peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Tempus AI, Inc. Profitability — ROE, Margins, and Quality Score

Tempus AI, Inc. (TEM) earns a quality factor score of 24/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -54.3%, compared to the Technology sector average of -1.4%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -11.7% versus the sector average of -1.0%.

On a margin basis, Tempus AI, Inc. reports gross margins of 63.0%, compared to 50.9% for the sector. The operating margin is -23.6% (sector: -0.5%). Net profit margin stands at -26.5%, versus -1.5% for the average Technology stock. Revenue growth is running at 101.4% on a trailing basis, compared to 14.2% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

TEM Debt, Balance Sheet, and Financial Health

Tempus AI, Inc. has a debt-to-equity ratio of 363.0%, compared to the Technology sector average of 43.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 3.13x, indicating strong short-term liquidity. Total debt on the balance sheet is $1.25B. Cash and equivalents stand at $656M.

TEM has a beta of 2.26, meaning it is more volatile than the broader market — a $10,000 investment in TEM would be expected to move 126.3% more than the S&P 500 on any given day. The stability factor score for Tempus AI, Inc. is 28/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Tempus AI, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Tempus AI, Inc. reported revenue of $1.09B and earnings per share (EPS) of $-1.41. Net income for the quarter was $-267M. Gross margin was 63.0%. Operating income came in at $-245M.

In FY 2025, Tempus AI, Inc. reported revenue of $1.27B and earnings per share (EPS) of $-1.41. Net income for the quarter was $-245M. Revenue grew 83.4% year-over-year compared to FY 2024. Operating income came in at $-253M.

In Q3 2025, Tempus AI, Inc. reported revenue of $334M and earnings per share (EPS) of $-0.46. Net income for the quarter was $-80M. Revenue grew 84.7% year-over-year compared to Q3 2024. Operating income came in at $-61M.

In Q2 2025, Tempus AI, Inc. reported revenue of $315M and earnings per share (EPS) of $-0.25. Net income for the quarter was $-43M. Revenue grew 89.6% year-over-year compared to Q2 2024. Operating income came in at $-62M.

Over the past 8 quarters, Tempus AI, Inc. has demonstrated a growth trajectory, with revenue expanding from $166M to $1.09B. Investors analyzing TEM stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TEM Dividend Yield and Income Analysis

Tempus AI, Inc. (TEM) does not currently pay a dividend. This is common among smaller companies in the Computer Software industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Technology dividend stocks may want to explore other Technology stocks or use the stock screener to filter by dividend yield.

TEM Momentum and Technical Analysis Profile

Tempus AI, Inc. (TEM) has a momentum factor score of 26/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 37/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

TEM vs Competitors — Technology Sector Ranking and Peer Comparison

Within the Technology sector, Tempus AI, Inc. (TEM) ranks #507 out of 584 stocks based on the Blank Capital composite score. This places TEM in the lower half of all Technology stocks in our coverage universe. Key competitors and sector peers include IHS Holding Ltd (IHS) with a score of 55.0/100, VERISIGN INC/CA (VRSN) with a score of 56.0/100, ESCO TECHNOLOGIES INC (ESE) with a score of 51.7/100, CareCloud, Inc. (CCLD) with a score of 46.9/100, and MMTec, Inc. (MTC) with a score of 47.4/100.

Comparing TEM against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TEM vs S&P 500 (SPY) comparison to assess how Tempus AI, Inc. stacks up against the broader market across all factor dimensions.

TEM Next Earnings Date

No upcoming earnings date has been announced for Tempus AI, Inc. (TEM) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TEM? — Investment Thesis Summary

The quantitative profile for Tempus AI, Inc. suggests caution. The quality score of 24/100 flags below-average profitability. The value score of 30/100 indicates premium valuation. Momentum is weak at 26/100, a headwind for near-term performance. High volatility (stability score 28/100) increases portfolio risk.

In summary, Tempus AI, Inc. (TEM) earns a Avoid rating with a composite score of 26.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TEM stock.

Related Resources for TEM Investors

Explore more research and tools: TEM vs S&P 500 comparison, top Technology stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TEM head-to-head with peers: TEM vs IHS, TEM vs VRSN, TEM vs ESE.